AR063451A1 - Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas. - Google Patents
Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas.Info
- Publication number
- AR063451A1 AR063451A1 ARP070104876A ARP070104876A AR063451A1 AR 063451 A1 AR063451 A1 AR 063451A1 AR P070104876 A ARP070104876 A AR P070104876A AR P070104876 A ARP070104876 A AR P070104876A AR 063451 A1 AR063451 A1 AR 063451A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- heteroaryl
- aryl
- heterocyclyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 2-oxazolyl Chemical group 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 abstract 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 abstract 1
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 abstract 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 abstract 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 abstract 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 abstract 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 abstract 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 abstract 1
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85607906P | 2006-11-02 | 2006-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063451A1 true AR063451A1 (es) | 2009-01-28 |
Family
ID=39233054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104876A AR063451A1 (es) | 2006-11-02 | 2007-11-01 | Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas. |
| ARP110100026A AR079840A2 (es) | 2006-11-02 | 2011-01-05 | Receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabicicloalcanos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100026A AR079840A2 (es) | 2006-11-02 | 2011-01-05 | Receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabicicloalcanos |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8114889B2 (https=) |
| EP (2) | EP2284171B1 (https=) |
| JP (2) | JP5539723B2 (https=) |
| KR (2) | KR101415705B1 (https=) |
| CN (4) | CN102942569B (https=) |
| AR (2) | AR063451A1 (https=) |
| AT (2) | ATE509022T1 (https=) |
| AU (2) | AU2007317433B2 (https=) |
| BR (2) | BRPI0717930A2 (https=) |
| CA (1) | CA2663925C (https=) |
| CL (1) | CL2007003155A1 (https=) |
| CO (1) | CO6180435A2 (https=) |
| CY (1) | CY1112374T1 (https=) |
| DK (1) | DK2094703T3 (https=) |
| ES (2) | ES2395157T3 (https=) |
| HR (1) | HRP20110570T1 (https=) |
| IL (2) | IL197618A (https=) |
| MX (1) | MX2009004801A (https=) |
| MY (2) | MY156730A (https=) |
| NO (1) | NO20091251L (https=) |
| NZ (2) | NZ587847A (https=) |
| PE (2) | PE20081441A1 (https=) |
| PL (1) | PL2094703T3 (https=) |
| PT (1) | PT2094703E (https=) |
| RS (1) | RS51834B (https=) |
| RU (2) | RU2448969C2 (https=) |
| SA (1) | SA07280584B1 (https=) |
| SI (1) | SI2094703T1 (https=) |
| TW (3) | TWI454262B (https=) |
| UA (2) | UA98944C2 (https=) |
| UY (1) | UY30686A1 (https=) |
| WO (1) | WO2008057938A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454262B (zh) * | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| JP2011513421A (ja) * | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| WO2009113950A1 (en) * | 2008-03-10 | 2009-09-17 | Astrazeneca Ab | Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist |
| WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
| WO2010028033A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| WO2010028011A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| RU2417082C2 (ru) * | 2009-07-14 | 2011-04-27 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения |
| PT2513085T (pt) | 2009-11-18 | 2016-11-14 | Suven Life Sciences Ltd | Compostos bicíclicos como ligantes do recetor da acetilcolina nicotínico alfa4beta2 |
| AU2010337837B2 (en) | 2009-12-29 | 2013-09-05 | Suven Life Sciences Limited | Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| EP3848028B9 (en) | 2014-10-20 | 2024-10-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112017026682A2 (pt) * | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| AU2016328436B2 (en) * | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| MX385698B (es) | 2016-04-07 | 2025-03-18 | Oyster Point Pharma Inc | Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
| HUT74682A (en) * | 1993-12-29 | 1997-01-28 | Pfizer | Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them |
| US5457121A (en) | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| US6815438B2 (en) * | 1999-12-14 | 2004-11-09 | Neurosearch A/S | Heteroaryl-diazabicycloalkanes |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| EP1368354A1 (en) | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| AU2002320958B2 (en) | 2001-07-06 | 2008-02-28 | Neurosearch A/S | Novel compounds, their preparation and use |
| SE0202465D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| CN1317280C (zh) * | 2003-02-27 | 2007-05-23 | 神经研究公司 | 新的二氮杂双环芳基衍生物 |
| DE602004023586D1 (de) * | 2003-02-27 | 2009-11-26 | Neurosearch As | Neue diazabicyclische arylderivate |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| ATE382623T1 (de) * | 2004-06-09 | 2008-01-15 | Hoffmann La Roche | Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln |
| WO2006012470A1 (en) | 2004-07-22 | 2006-02-02 | Cumbre Pharmaceuticals Inc. | Rifamycin derivatives for treating microbial infections |
| ES2434467T3 (es) * | 2005-05-13 | 2013-12-16 | Lexicon Pharmaceuticals, Inc. | Compuestos multicíclicos y métodos para su uso |
| TWI454262B (zh) * | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
-
2007
- 2007-10-19 TW TW101139986A patent/TWI454262B/zh not_active IP Right Cessation
- 2007-10-19 TW TW099135628A patent/TWI404532B/zh not_active IP Right Cessation
- 2007-10-19 TW TW096139391A patent/TWI405763B/zh not_active IP Right Cessation
- 2007-10-30 SA SA07280584A patent/SA07280584B1/ar unknown
- 2007-10-31 PE PE2007001487A patent/PE20081441A1/es not_active Application Discontinuation
- 2007-10-31 PE PE2011000136A patent/PE20110671A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703155A patent/CL2007003155A1/es unknown
- 2007-11-01 RU RU2009120674/04A patent/RU2448969C2/ru not_active IP Right Cessation
- 2007-11-01 RU RU2009138600/04A patent/RU2517693C2/ru not_active IP Right Cessation
- 2007-11-01 RS RS20110339A patent/RS51834B/sr unknown
- 2007-11-01 UA UAA200905474A patent/UA98944C2/ru unknown
- 2007-11-01 JP JP2009535465A patent/JP5539723B2/ja active Active
- 2007-11-01 BR BRPI0717930-8A patent/BRPI0717930A2/pt not_active IP Right Cessation
- 2007-11-01 CN CN201210401679.6A patent/CN102942569B/zh not_active Expired - Fee Related
- 2007-11-01 CN CN201210291637.1A patent/CN102838605B/zh not_active Expired - Fee Related
- 2007-11-01 CN CN2010105367790A patent/CN102020646B/zh not_active Expired - Fee Related
- 2007-11-01 AR ARP070104876A patent/AR063451A1/es not_active Application Discontinuation
- 2007-11-01 MY MYPI2011004927A patent/MY156730A/en unknown
- 2007-11-01 UY UY30686A patent/UY30686A1/es not_active Application Discontinuation
- 2007-11-01 AU AU2007317433A patent/AU2007317433B2/en not_active Ceased
- 2007-11-01 ES ES10075738T patent/ES2395157T3/es active Active
- 2007-11-01 NZ NZ587847A patent/NZ587847A/en not_active IP Right Cessation
- 2007-11-01 EP EP10075738A patent/EP2284171B1/en active Active
- 2007-11-01 PL PL07863786T patent/PL2094703T3/pl unknown
- 2007-11-01 WO PCT/US2007/083330 patent/WO2008057938A1/en not_active Ceased
- 2007-11-01 CN CN2007800402281A patent/CN101528745B/zh not_active Expired - Fee Related
- 2007-11-01 KR KR1020097008122A patent/KR101415705B1/ko not_active Expired - Fee Related
- 2007-11-01 US US12/447,850 patent/US8114889B2/en not_active Expired - Fee Related
- 2007-11-01 EP EP07863786A patent/EP2094703B1/en active Active
- 2007-11-01 SI SI200730628T patent/SI2094703T1/sl unknown
- 2007-11-01 BR BRPI0722387-0A patent/BRPI0722387A2/pt not_active Application Discontinuation
- 2007-11-01 NZ NZ575557A patent/NZ575557A/en not_active IP Right Cessation
- 2007-11-01 DK DK07863786.5T patent/DK2094703T3/da active
- 2007-11-01 AT AT07863786T patent/ATE509022T1/de active
- 2007-11-01 UA UAA200912807A patent/UA106718C2/uk unknown
- 2007-11-01 HR HR20110570T patent/HRP20110570T1/hr unknown
- 2007-11-01 CA CA2663925A patent/CA2663925C/en not_active Expired - Fee Related
- 2007-11-01 MX MX2009004801A patent/MX2009004801A/es active IP Right Grant
- 2007-11-01 KR KR1020107025973A patent/KR20100124356A/ko not_active Abandoned
- 2007-11-01 AT AT10075738T patent/ATE545646T1/de active
- 2007-11-01 ES ES07863786T patent/ES2395212T3/es active Active
- 2007-11-01 MY MYPI20091569A patent/MY145602A/en unknown
- 2007-11-01 PT PT07863786T patent/PT2094703E/pt unknown
-
2009
- 2009-03-16 IL IL197618A patent/IL197618A/en not_active IP Right Cessation
- 2009-03-26 NO NO20091251A patent/NO20091251L/no not_active Application Discontinuation
- 2009-06-01 CO CO09056352A patent/CO6180435A2/es active IP Right Grant
-
2010
- 2010-03-15 US US12/723,790 patent/US8268860B2/en not_active Expired - Fee Related
- 2010-09-07 AU AU2010219323A patent/AU2010219323B2/en not_active Ceased
- 2010-10-31 IL IL209026A patent/IL209026A/en not_active IP Right Cessation
-
2011
- 2011-01-05 AR ARP110100026A patent/AR079840A2/es not_active Application Discontinuation
- 2011-07-20 CY CY20111100706T patent/CY1112374T1/el unknown
-
2012
- 2012-01-03 US US13/342,635 patent/US8859609B2/en active Active
- 2012-07-23 US US13/555,458 patent/US8921410B2/en active Active
- 2012-11-19 JP JP2012253103A patent/JP5739398B2/ja active Active
-
2014
- 2014-11-24 US US14/551,498 patent/US20150080576A1/en not_active Abandoned
-
2015
- 2015-10-26 US US14/922,473 patent/US9580434B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063451A1 (es) | Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas. | |
| ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| JP2022516469A5 (https=) | ||
| JP2017537940A5 (https=) | ||
| NZ574405A (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| JP2015520769A5 (https=) | ||
| JP2020504142A5 (https=) | ||
| JP2019510034A5 (https=) | ||
| BR112015001201B1 (pt) | Compostos anti-infecciosos 5,5-heteroaromáticos e composição | |
| JP2017513842A5 (https=) | ||
| JP2019510027A5 (https=) | ||
| JP2012513416A5 (https=) | ||
| JP2017531619A5 (https=) | ||
| JP2021535112A5 (https=) | ||
| JP2017524733A5 (https=) | ||
| JP2014506582A5 (https=) | ||
| CN109689042A (zh) | 用于治疗黄斑变性的与恩他卡朋相关的化合物 | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| CA2653830A1 (en) | 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor | |
| JP2016525104A5 (https=) | ||
| AR065705A1 (es) | Subtipo de amidas selectivas de diazabicicloalcanos | |
| JP2019500376A5 (https=) | ||
| JP2010514733A5 (https=) | ||
| AR114930A1 (es) | Composición farmacéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |